Իսրայել - եբրայերեն - Ministry of Health

boehringer ingelheim israel ltd. - pramipexole dihydrochloride monohydrate - טבליות עם שחרור נרחב - pramipexole dihydrochloride monohydrate 0.75 mg - pramipexole - pramipexole - treatment of signs and symptoms of idiopathic parkinson's disease, as monotherapy or in combination with levodopa.

Իսրայել - եբրայերեն - Ministry of Health

boehringer ingelheim israel ltd. - pramipexole dihydrochloride monohydrate - טבליות עם שחרור נרחב - pramipexole dihydrochloride monohydrate 1.5 mg - pramipexole - pramipexole - treatment of signs and symptoms of idiopathic parkinson's disease, as monotherapy or in combination with levodopa.

Իսրայել - եբրայերեն - Ministry of Health

glaxo smith kline (israel) ltd - dutasteride; tamsulosin hydrochloride - קפסולות - dutasteride 0.5 mg; tamsulosin hydrochloride 0.4 mg - tamsulosin

Իսրայել - եբրայերեն - Ministry of Health

glaxo smith kline (israel) ltd - dutasteride; tamsulosin hydrochloride - קפסולות - dutasteride 0.5 mg; tamsulosin hydrochloride 0.4 mg - tamsulosin

Իսրայել - եբրայերեն - Ministry of Health

glaxo smith kline (israel) ltd - dutasteride; tamsulosin hydrochloride - קפסולות - dutasteride 0.5 mg; tamsulosin hydrochloride 0.4 mg - tamsulosin

Իսրայել - եբրայերեն - Ministry of Health

rafa laboratories ltd - phenoxybenzamine hydrochloride - קפסולות - phenoxybenzamine hydrochloride 10 mg - phenoxybenzamine - phenoxybenzamine - pheochromocytoma, benign prostatic hypertrophy.

Իսրայել - եբրայերեն - Ministry of Health

padagis israel pharmaceuticals ltd, israel - butenafine hydrochloride - קרם - butenafine hydrochloride 1 % - butenafine - butenafine - interdigital tinea pedis, tinea coporis, tinea cruris . (treatment in tinea coporis and tinea cruris is limited to up to 4 weeks).

Իսրայել - եբրայերեն - Ministry of Health

intervet ( israel) ltd - oxytetracycline hydrochloride - oxytetracycline hydrochloride 25 mg/ml

Իսրայել - եբրայերեն - Ministry of Health

unipharm ltd, israel - atorvastatin as calcium trihydrate salt - טבליה - atorvastatin as calcium trihydrate salt 10 mg - atorvastatin - atorvastatin - torid is indicated as an adjunct to diet for reduction of elevated total cholesterol ldl- cholesterol apolipoprotein b and triglycerides and to increase hdl cholesterol in patients with primary hypercholesterolaemia including familial hypercholesterolaemia (heterozygous variant) or combined (mixed) hyperlipidaemia (corresponding to types iia and iib of the fredrickson classification) when response to diet and other nonpharmacological measures is inadequate. torid is also indicated to reduce total-c and ldl -c in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatment (e.g. ldl apheresis) or if such treatments are unavailable. pediatric patients (10-17 years of age) : atorvastatin is indicated as an adjunct to diet to reduce total -c ldl-c and apo b levels in boys and postmenarchal girls 10 to 17 years of age with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: 1. ldl-c remains >or = 190 mg/

Իսրայել - եբրայերեն - Ministry of Health

unipharm ltd, israel - atorvastatin as calcium trihydrate salt - טבליה - atorvastatin as calcium trihydrate salt 20 mg - atorvastatin - atorvastatin - torid is indicated as an adjunct to diet for reduction of elevated total cholesterol ldl- cholesterol apolipoprotein b and triglycerides and to increase hdl cholesterol in patients with primary hypercholesterolaemia including familial hypercholesterolaemia (heterozygous variant) or combined (mixed) hyperlipidaemia (corresponding to types iia and iib of the fredrickson classification) when response to diet and other nonpharmacological measures is inadequate. torid is also indicated to reduce total-c and ldl -c in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatment (e.g. ldl apheresis) or if such treatments are unavailable. pediatric patients (10-17 years of age) : atorvastatin is indicated as an adjunct to diet to reduce total -c ldl-c and apo b levels in boys and postmenarchal girls 10 to 17 years of age with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: 1. ldl-c remains >or = 190 mg/